BioLineRx Ltd. In-Licenses Innovative Platform For The Treatment Of Neurological Disorders From Tel Aviv And Bar-Ilan Research & Development Co. Ltd.
10/19/2005 5:11:12 PM
BioLineRx Ltd., Israel's only specialized drug development company, today announced that it has signed an in-license agreement covering the development of novel compounds for the treatment of neurological disorders including schizophrenia, neurodegenerative disease and cancer. The worldwide exclusive license agreement was signed with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, and Bar Ilan Research & Development Company Ltd. (BIRAD), the technology transfer office of Bar Ilan University for technologies developed by leading scientists and physicians at their universities.
comments powered by